GleamWall
中文EN

TECH BIO-TECHNE Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 842023 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.9%
TTM net income YoY120.5%
TTM EPS YoY124.5%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-11.3%

Margins

Gross margin65.8%
Operating margin19.6%
Net margin14.0%
FCF margin25.1%
EBITDA margin27.5%

Returns

ROE8.3%
ROA6.7%
ROIC (approx.)9.3%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.00x
Current ratio2.28x
Interest coverage27.16x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-6.4%
Payout ratio29.1%
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2026*2026-06-30FY20252025-06-30
Income statement
Revenue$1.22B$1.22B
Cost of revenue$415.97M$429.36M
Gross profit$799.07M$790.27M
R&D expense$94.77M$99.50M
SG&A expense$452.42M$588.52M
Operating income$251.89M$102.25M
Interest expense$9.63M$8.51M
Pretax income$240.68M$98.46M
Income tax$58.82M$25.06M
Net income$181.86M$73.40M
EBITDA$349.25M$212.16M
EPS (basic)1.170.47
EPS (diluted)1.160.46
Dividends declared per share0.320.32
Weighted avg. shares (diluted)157.01M159.72M
Balance sheet
Cash & equivalents$264.71M$162.19M
Receivables$216.59M$206.88M
Inventory$195.74M$189.45M
Current assets$744.40M$608.30M
PP&E, net$231.84M$245.72M
Goodwill$975.36M$980.93M
Intangibles$303.46M$365.60M
Total assets$2.59B$2.56B
Current liabilities$163.70M$175.85M
Long-term debt$200.00M$346.00M
Total debt$200.00M$346.00M
Total liabilities$478.50M$639.06M
Shareholders' equity$2.11B$1.92B
Net debt-$64.71M$183.81M
Shares outstanding156.10M154.97M
Cash flow statement
Operating cash flow$292.07M$287.56M
Capital expenditure$28.85M$31.01M
Free cash flow$263.22M$256.55M
Investing cash flow-$18.19M-$35.18M
Financing cash flow-$169.11M-$253.91M
Depreciation & amortization$97.36M$109.90M
Stock-based compensation$41.37M$40.83M
Dividends paid$49.92M$50.39M
Share buybacks$41.67M$275.73M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.